Elenae Therapeutics

Elenae Therapeutics is a pre-clinical stage biotechnology company focused on developing a novel class of small molecule therapeutics that target RNA-protein interactions. Co-founded by renowned MIT and Whitehead Institute professors Robert Langer, Daniel Anderson, and Richard Young, the company leverages a proprietary platform to identify and modulate previously undruggable RNA-binding proteins (RBPs). By disrupting or enhancing these interactions, Elenae aims to address high-value targets in oncology and other complex diseases where RNA regulation is dysregulated. The company's approach represents a shift toward targeting the RNA-protein interactome to achieve precision control over gene expression. Headquartered in Cambridge, Massachusetts, Elenae Therapeutics is backed by leading venture capital firms such as Polaris Partners. The company is currently operating in stealth mode, focusing on the foundational science required to translate RNA-protein modulation into clinical candidates.